New hope for anxiety? trial tests potential alternative treatment
NCT ID NCT07330648
Summary
This study is testing a new medication called crisugabalin to see if it can safely reduce anxiety symptoms better than a placebo or an existing drug. It involves 216 Chinese adults with generalized anxiety disorder. Participants are randomly assigned to receive either the new drug, a placebo (inactive pill), or the standard drug venlafaxine for 8 weeks, with an optional 4-week follow-up phase.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.